For instance, BRCA2-deficient cancer cells are more dependent on PARP1 to repair DNA for survival, resulting in an increased sensitivity to PARP1 inhibitors [88], which kill the cancer cells through the genetic concept of synthetic lethality [89]. This evidence concerns the gene PARP1 and cancer.